Leerink Partnrs Estimates Nkarta FY2024 Earnings

Nkarta, Inc. (NASDAQ:NKTX) – Investment analysts at Leerink Partnrs issued their FY2024 earnings per share (EPS) estimates for Nkarta in a report issued on Thursday, February 13th. Leerink Partnrs analyst D. Graybosch anticipates that the company will earn ($1.77) per share for the year. The consensus estimate for Nkarta’s current full-year earnings is ($1.68) per share. Leerink Partnrs also issued estimates for Nkarta’s Q4 2024 earnings at ($0.46) EPS, Q1 2025 earnings at ($0.51) EPS, Q2 2025 earnings at ($0.45) EPS, Q3 2025 earnings at ($0.46) EPS, Q4 2025 earnings at ($0.47) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($2.16) EPS, FY2027 earnings at ($2.10) EPS and FY2028 earnings at ($1.86) EPS.

Other equities research analysts have also issued research reports about the company. HC Wainwright dropped their target price on Nkarta from $22.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 11th. Needham & Company LLC lowered their price objective on Nkarta from $13.00 to $11.00 and set a “buy” rating on the stock in a research report on Friday, November 8th. Finally, Mizuho lowered their price objective on Nkarta from $20.00 to $16.00 and set an “outperform” rating on the stock in a research report on Thursday, November 21st. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $15.00.

Nkarta Stock Up 2.7 %

Shares of NASDAQ NKTX opened at $2.27 on Monday. The business’s 50 day moving average price is $2.34 and its 200 day moving average price is $3.53. The firm has a market cap of $160.19 million, a P/E ratio of -1.21 and a beta of 0.85. Nkarta has a 52 week low of $1.96 and a 52 week high of $16.24.

Insider Transactions at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of the company’s stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the transaction, the chief executive officer now directly owns 319,859 shares of the company’s stock, valued at $703,689.80. This represents a 5.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Corporate insiders own 8.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in NKTX. The Manufacturers Life Insurance Company raised its stake in shares of Nkarta by 92.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 20,710 shares of the company’s stock worth $122,000 after buying an additional 9,975 shares during the period. SG Americas Securities LLC acquired a new position in shares of Nkarta during the 3rd quarter worth approximately $93,000. Intech Investment Management LLC acquired a new position in shares of Nkarta during the 3rd quarter worth approximately $74,000. FMR LLC raised its stake in shares of Nkarta by 97.1% during the 3rd quarter. FMR LLC now owns 133,149 shares of the company’s stock worth $602,000 after buying an additional 65,600 shares during the period. Finally, Wasatch Advisors LP raised its stake in shares of Nkarta by 31.7% during the 3rd quarter. Wasatch Advisors LP now owns 1,834,680 shares of the company’s stock worth $8,293,000 after buying an additional 442,125 shares during the period. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.